| Literature DB >> 22257637 |
Eduardo Azziz-Baumgartner1, Mustafizur Rahman, Abdullah Al Mamun, Mohammad Sabbir Haider, Rashid Uz Zaman, Polash Chandra Karmakar, Sharifa Nasreen, Syeda Mah-E Muneer, Nusrat Homaira, Doli Rani Goswami, Be-Nazir Ahmed, Mohammad Mushtuq Husain, Khondokar Mahbuba Jamil, Selina Khatun, Mujaddeed Ahmed, Apurba Chakraborty, Alicia Fry, Marc-Alain Widdowson, Joseph Bresee, Tasnim Azim, A S M Alamgir, Abdullah Brooks, Mohamed Jahangir Hossain, Alexander Klimov, Mahmudur Rahman, Stephen P Luby.
Abstract
To explore Bangladesh's ability to detect novel influenza, we examined a series of laboratory-confirmed pandemic (H1N1) 2009 cases. During June-July 2009, event-based surveillance identified 30 case-patients (57% travelers); starting July 29, sentinel sites identified 252 case-patients (1% travelers). Surveillance facilitated response weeks before the spread of pandemic (H1N1) 2009 infection to the general population.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22257637 PMCID: PMC3310083 DOI: 10.3201/eid1801.101996
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Location of 12 sentinel-site surveillance hospitals (red crosses) and of persons confirmed as infected with pandemic (H1N1) 2009 virus during June 2009–October 2010, Bangladesh. Open circles indicate case-patients identified during 2009; solid circles indicate case-patients identified during 2010. Testing was conducted on the basis of cases of severe pneumonia in hospitalized case-patients (<5 years of age), severe acute respiratory infection in hospitalized case-patients (>5 years of age), influenza-like illness, and acute respiratory infection in ambulatory case-patients (all age groups) identified as part of event-based, sentinel-site, and community-based surveillance systems.
Demographics of confirmed case-patients with pandemic (H1N1) 2009 virus by surveillance platform, Bangladesh, June 2009–October 2010
| Surveillance type | Age, median (range) | No. (%) female patients | No. (%) travelers |
|---|---|---|---|
| Event-based, n = 182 | 24 y (4 mo–72 y) | 71 (39) | 51 (28)* |
| Sentinel-site, n = 527 | 20 y (1 mo–70 y) | 182 (35)† | 21 (4) |
| Kamalapur community-based, n = 621 | 6 y (3 mo–76 y)‡ | 303 (49) | 0 |
| Mirpur community-based, n = 41 | 16 mo (3–26 mo) | 17 (41) | 2 (5) |
*Comparison between event-based vs. other surveillance sites, Pearson χ2 p<0.0001. †Comparison between sentinel-based vs. other surveillance sites, Pearson χ2 p<0.0001. ‡Comparison between Kamalapur-based vs. other surveillance sites, rank-sum p<0.0001.
Figure 2Date of onset of confirmed illness in case-patients with pandemic (H1N1) 2009 by surveillance platform, May 2009–October 2010, Bangladesh.
Clinical description of case-patients infected with pandemic (H1N1) 2009 virus seeking treatment, by surveillance platform, Bangladesh, June 2009–October 2010
| Description of case-patient | Event-based surveillance, n = 182 (%) | Sentinel-site surveillance, n = 527 (%) | Kamalapur community-based surveillance, n = 621 (%) | Mirpur community-based surveillance, n = 41 (%) |
|---|---|---|---|---|
| At high risk for complications from influenza illness | 79 (43) | 331 (63) | 285 (4) | 41 (100) |
| Preexisting conditions* | 54 (30)† | 182 (35) | 22 (3) | 0 |
| Danger signs (i.e., difficulty breathing or shortness of breath) | 50 (27 )† | 230 (44) | 47 (8) | 5( 12) |
| Treated with oseltamivir‡ when treatment indicated† | 4/56 (84) | 7/207 (3) | 81/272 (30) | 1/41 (2) |
| Median days from symptom onset to treatment with oseltamivir | 2 (2–4) | 5 (2–8) | 4 (1–5) | 5 |
| Hospitalization | 29 (16)† | 259 (49) | 0 | 0 |
| Death | 3 (2)† | 25 (5) | 0 | 0 |
*Preexisting conditions among event and sentinel site surveillance case-patients included asthma (71[10%]), chronic obstructive lung disease (31 [4%]), obesity (47 [7%]), immune suppression (20 [3%]), diabetes (12 [2%]), chronic heart disease (10 [1%]), neuromuscular disorders (10 [1%]), liver disease (10 [1%]), and hematologic disorders (8 [1%]), cancer (3 [0.4%]), and pregnancy (3 [0.4%]), while 2 community-based surveillance case-patients had immunosuppression (0.3%), 2 (0.3%) had asthma, and 1 (0.1%) had diabetes. †Comparison between surveillance sites, Pearson χ2 p<0.0001. ‡Oseltamivir 5 mg 2×/d for 5 days.